title: Longitudinal effect of tiludronate on bone mineral density, resonant frequency, and strength in monkeys.
abstract: The effect of Tiludronate on bone was studied in 72 growing monkeys (Papio papio), 36 males and 36 females, aged 4-7 years. They were randomly allocated into four groups (18 animals per group, 9 males and 9 females): group I, controls; group II, 10 mg/kg/day; group III, 20 mg/kg/day; and group IV, 40 mg/kg/day of Tiludronate. A total of 12 animals (6 males and 6 females) in each group were sacrificed at the end of treatment (1 year) and 6 animals (3 males and 3 females) per group 1 year later. Bone mineral density (BMD) was measured by dual-photon absorptiometry. Biomechanical properties were evaluated by an impact torsion test and by resonant frequency analysis. Bone mineral measurements indicated that at the end of 1 year of treatment BMD was significantly higher, especially at the distal epiphysis of the radius, than in controls. No significant differences between groups were found in BMD 1 year after stopping treatment. Biomechanical analyses indicated that torsional stiffness increased after treatment. No differences between groups were found 1 year after stopping treatment. Results of resonant frequencies indicated an increased calculated transversal stiffness after treatment and 1 year later and an increased buckling strength 1 year after stopping treatment. In conclusion, the results on the effect of Tiludronate in growing monkeys indicate a profound effect of this drug on bone density and biomechanical properties. The biomechanical results indicate that this drug is safe, with conservation of bone strength despite a change in intrinsic mechanical properties of the bone.
authors.affiliation: Arthritis and Metabolic Bone Disease Research Unit, Catholic University of Leuven, Pellenberg, Belgium.
authors.forename: P
authors.initials: P
authors.lastname: Geusens
authors.forename: J
authors.initials: J
authors.lastname: Nijs
authors.forename: G
authors.initials: G
authors.lastname: Van der Perre
authors.forename: R
authors.initials: R
authors.lastname: Van Audekercke
authors.forename: G
authors.initials: G
authors.lastname: Lowet
authors.forename: S
authors.initials: S
authors.lastname: Goovaerts
authors.forename: A
authors.initials: A
authors.lastname: Barbier
authors.forename: F
authors.initials: F
authors.lastname: Lacheretz
authors.forename: B
authors.initials: B
authors.lastname: Remandet
authors.forename: Y
authors.initials: Y
authors.lastname: Jiang
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D001842:Bone and Bones / Q000502:physiology*; D004164:Diphosphonates / Q000008:administration & dosage*; D005260:Female; D008137:Longitudinal Studies; D008297:Male; D010215:Papio; D014102:Torsion Abnormality
chemical_list: D004164:Diphosphonates; C058651:tiludronic acid